Idorsia.com
  • Home
  • About Idorsia
    • Idorsia today
      • Our strategy
      • Our Drug Discovery approach
      • Our pipeline
      • History
    • Idorsia people
      • Our behaviors
      • Leaders
      • Board of Directors
    • Target diseases
      • Fabry disease
      • Insomnia
      • Cerebral vasospasm
      • Resistant Hypertension
      • Lupus
    • Partnerships
  • Our responsibilities
    • Our Approach
    • Our People
    • Stakeholder Engagement
    • Environment
    • Our Communities
    • Policies & Charters
  • Investors
    • Results Day Center
    • Our equity story
      • Company strategy
      • Development Pipeline
      • Corporate Governance & Sustainability
    • Financial information
      • Financial archive
    • Corporate Reports
    • News & Events
      • Media releases
      • AGM
      • Pipeline webcasts
        • Clazosentan Phase 3 advancing
        • Nemorexant Phase 3 initiation
        • Lucerastat Phase 3 initation
      • Financial reporting webcast
    • Stock information
      • Stock chart tool
      • Covering analysts
      • Consensus estimate
  • Media
    • Newsroom
    • News archive
    • Media center
    • Social media
    • Resources in German
  • Careers
    • Working@Idorsia
      • Recruitment, Development & Retention
      • Diversity & Inclusion
      • Recognition
      • Health, Safety & Well-being
    • Job opportunities
    • Living in Basel
    • FAQ
      • Privacy policy
  • Contact
    • Data Protection Officer
More hope&nbsp;&ndash;<br />Pioneering <br />therapiesMore hope&nbsp;&ndash;<br />Pioneering <br />therapies

More hope –
Pioneering
therapies

Site map

About Idorsia

Link to /about-idorsia/index
  • Idorsia today
    • Our strategy
    • Our Drug Discovery approach
    • Our pipeline
    • History
  • Idorsia people
    • Our behaviors
    • Leaders
    • Board of Directors
  • Target diseases
    • Fabry disease
    • Insomnia
    • Cerebral vasospasm
    • Resistant Hypertension
    • Lupus
  • Partnerships
 

Our responsibilities

Link to /our-responsibilities/index
  • Our Approach
  • Our People
  • Stakeholder Engagement
  • Environment
  • Our Communities
  • Policies & Charters
 

Investors

Link to /investors/index
  • Results Day Center
  • Our equity story
    • Company strategy
    • Development Pipeline
    • Corporate Governance & Sustainability
  • Financial information
    • Financial archive
  • Corporate Reports
  • News & Events
    • Media releases
      • AGM
      • Pipeline webcasts
        • Clazosentan Phase 3 advancing
        • Nemorexant Phase 3 initiation
        • Lucerastat Phase 3 initation
      • Financial reporting webcast
    • Stock information
      • Stock chart tool
      • Covering analysts
      • Consensus estimate
     

    Media

    Link to /media/index
    • Newsroom
    • News archive
      • Media center
      • Social media
      • Resources in German
         

        Careers

        Link to /careers/index
        • Working@Idorsia
          • Recruitment, Development & Retention
          • Diversity & Inclusion
          • Recognition
          • Health, Safety & Well-being
        • Job opportunities
        • Living in Basel
        • FAQ
          • Privacy policy
         

        Contact

        Link to /contact/index
        • Data Protection Officer
         
        Follow us:
        Viewing options

        This website is subject to the terms and conditions outlined in the legal and privacy statement.

        Last update: 24.04.2018

        Legal & privacy statement|Site map|Cookie policy|Webmaster

        Copyright © 2018 Idorsia Pharmaceuticals Ltd